Q-omics provides the consensus-scored C1GALT1C1L profile across patient tissues and cancer cell-line models. C1GALT1C1L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, C1GALT1C1L is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, C1GALT1C1L RNA expression shows 18,138 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, KICH, and ACC as cancer lineages where C1GALT1C1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C1GALT1C1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C1GALT1C1L survival associations across molecular data types. C1GALT1C1L RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C1GALT1C1L RNA expression–survival associations across cancer types. High C1GALT1C1L expression shows unfavorable associations in STAD, ACC, LGG, UVM and COAD, but favorable associations in THYM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for C1GALT1C1L RNA expression.
This table summarizes C1GALT1C1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for C1GALT1C1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C1GALT1C1L shows lower tumor expression in KICH, THCA, BRCA, KIRP and UCEC and higher tumor expression in LUAD. The KICH box plot shows higher C1GALT1C1L RNA expression in normal versus tumor tissue (log2 FC = −2.188, t-test p < 0.001).
This table shows molecular features associated with C1GALT1C1L in patient tissues and cancer cell lines. In patient samples, C1GALT1C1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C1GALT1C1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
